In the Early Treatment Diabetic Retinopathy Study, treatment with 650 mg aspirin for 5 years was associated with a nonsignificant 9% reduction in the primary endpoint among diabetic patients.
Does low-dose aspirin prevent cardiovascular diseases in individuals with diabetes aged >40 years or with additional risk factors?
This commentary critiques the ADA/AHA recommendation for low-dose aspirin in primary prevention for diabetic patients, highlighting the limited supporting evidence.
Effect estimate: 9% reduction
p-value: p=nonsignificant
The recent American Diabetes Association/American Heart Association statement recommends the use of low doses of aspirin as a strategy for primary prevention of cardiovascular diseases in all individuals with diabetes aged >40 years or who have additional risk factors (1). Like in previous recommendations (2), only selected pieces of evidence are mentioned to support this statement. The data used to sustain the efficacy of aspirin come from the Early Treatment Diabetic Retinopathy Study, the only study specifically conducted in diabetic patients with and without previous cardiovascular disease (3). In this trial, treatment with 650 mg aspirin for 5 years was associated with a nonsignificant 9% reduction in the primary end …
Nicolucci et al. (Fri,) conducted a letter in Diabetes Mellitus. Aspirin was evaluated on primary endpoint (9% reduction, p=nonsignificant). In the Early Treatment Diabetic Retinopathy Study, treatment with 650 mg aspirin for 5 years was associated with a nonsignificant 9% reduction in the primary endpoint among diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: